Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next?

Xinhua Chen, Hao Liu, Guoxin Li, Jiang Yu

Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Correspondence to: Prof. Hao Liu, MD, PhD. Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Email: liuhaofbi@163.com; Prof. Guoxin Li, MD, PhD, FRCS. Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Email: gzliguoxin@163.com; Prof Jiang Yu, MD, PhD. Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Email: balbc@163.com.

Abstract

Postoperative adjuvant chemotherapy (ACT) confers superior gastric cancer (GC) survival in the Eastern cohort. However, is the current standard of ACT already excessive, or is it still necessary to increase its intensity for specific subgroups? Tailored ACT strategies for GC depend on gradual exploration by clinical trials in selected patients. Thus, understanding the implications of previous and current research can help us respond wisely and design effective, rational trials, save medical resources and make better decisions in clinical practice. After reviewing and analyzing studies on ACT for GC patients undergoing curative resection, we found that research strategies for conducting “addition” ACT for specific stages of the disease have achieved great progress in making ACT more tailored and personalized in consideration of pathology stages. Furthermore, trials indicate that “addition” ACT strategies for GC patient subgroups based on histological characteristics might be helpful to move toward a more specific tailored and personalized management approach. Designing ACT research focused on different node statuses should also be conducted according to the biological specificity of lymph node (LN) metastasis. Therefore, future trials designed to determine tailored treatment based on histological and biological characteristics for specific subgroups are urgently needed and conducted as the theme of the 2019 American Society of Clinical Oncology (ASCO): Caring for Every Patient, Learning from Every Patient.

Keywords: Gastric cancer (GC); adjuvant chemotherapy (ACT); clinical trial; tailored

Submitted Aug 29, 2019. Accepted for publication Nov 04, 2019. doi: 10.21147/j.issn.1000-9604.2019.06.05

View this article at: https://doi.org/10.21147/j.issn.1000-9604.2019.06.05

Introduction

Surgery remains the cornerstone of curative treatment for gastric cancer (GC). And currently, for locally advanced GC, laparoscopic gastrectomy is becoming the mainstream of surgical approach (1-2) while D2 lymphadenectomy is considered the standard of lymph node dissection (3-5). Compared with surgery alone, postoperative adjuvant chemotherapy (ACT) for GC can significantly improve survival in the Eastern cohort (6,7). A meta-analysis by the Global Advanced/Adjuvant Stomach Tumor Research International Collaboration (GASTRIC) group further confirmed that some regimes of postoperative ACT may promote survival (8). However, the limit of the expansion remains unknown, and it is unclear whether the current standard of ACT is already excessive or whether it is still necessary to increase its intensity. These questions need to be explored through clinical trials, as designing rational clinical trials to efficiently answer clinical questions requires gaining insight into the implications of previous and current clinical research on ACT. A rational approach can help save medical resources and permit better decisions in clinical practice. Thus, where should we go in the next trial?
This review aims to summarize subsequent directions for ACT exploration in selecting GC patients and improving efficiency of rational design of relevant clinical trials.

**“Addition” tendency in ACT trials for GC**

In 2011, the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) laid the foundation of ACT for curatively resected local advanced GC with the regimen of postoperative S-1 single-agent for 12 months (6). The 5-year follow-up data of 1,059 participants showed that the 5-year overall survival (OS) rate was 71.7% in the group receiving S-1 after surgery and 61.1% in the group receiving surgery only [hazard ratio (HR), 0.669; 95% confidence interval (95% CI), 0.540–0.828], respectively. The 5-year relapse-free survival (RFS) rate was 65.4% and 53.1%, respectively (HR, 0.653; 95% CI, 0.537–0.793). However, subgroup analysis showed that the 5-year OS rate of stage IIIB GC patients was 50.2% in the group receiving S-1 after surgery and 44.1% in the group receiving surgery-only (HR, 0.791; 95% CI, 0.520–1.205), indicating that some room for improvement remains. Therefore, further trials based on the pathology stage are needed to identify optimal adjuvant strategies.

However, it is not clear how subsequent studies should be conducted to further explore this topic. Previous research has implications for oncologists. The S-1 Plus cisplatin vs. S-1 In RCT In the Treatment for Stomach cancer (SPIRITS) trial (9) showed that the addition of cisplatin to S-1 significantly extended progression-free survival (PFS), whereas the V125 study (10) demonstrated that docetaxel plus cisplatin and fluorouracil is superior to cisplatin and fluorouracil with respect to survival in advanced GC. These studies have suggested that S-1 plus cisplatin and S-1 plus docetaxel are potentially better regimens for postoperative ACT for GC. Additionally, some trials have confirmed the feasibility of these regimes in a postoperative setting for GC (11,12). Therefore, it appears that enhancing the ACT intensity in later-stage GC subgroups is worth exploring. In the same way, a phase III RCT (RESCUE-GC study, ClinicalTrials.govNCT 02867839), which focused on evaluating S-1 plus oxaliplatin compared with S-1 alone in the adjuvant setting for stage II or IIIA gastric adenocarcinoma, is accruing patients in 13 Chinese institutions (13).

Accordingly, step-by-step “addition” ACT trials for specific-stage GC have been conducted. Shitara et al. proved that S-1 plus oxaliplatin ACT for stage III GC was manageable and safe based on the Japanese model (14). Fujitani et al. also demonstrated the feasibility and safety of postoperative ACT with S-1 plus docetaxel for stage III patients who had undergone D2 gastrectomy (15). The 3-year follow-up data further showed that the S-1 plus oxaliplatin regimen resulted in promising OS and DFS in stage IIIa GC patients, suggesting that this regime is a candidate for future phase III trials exploring optimal ACT strategies for selected GC patients. Additionally, Yoon et al. investigated the efficacy and safety of docetaxel, capecitabine and cisplatin (DXP) in patients with curatively resected stage IIIB–IV(M0) GC (16). Consistently, the adjuvant DXP regime was demonstrated to be feasible and effective in this trial, and the sequent phase III study comparing triplet and doublet regimens for these patients is ongoing. Similarly, a meta-analysis aimed at investigating the role of combination vs. single-agent ACT for GC also reported survival superiority for “addition” strategies of postoperative ACT in resectable GC (17). Compared with single-agent chemotherapy, postoperative combination chemotherapy conferred a 13% (HR, 0.87; 95% CI, 0.79–0.95; P=0.004) fixed reduction and a 19% (HR, 0.81; 95% CI, 0.68–0.97; P=0.02) random reduction in the risk of death in GC patients who had undergone radical resection. Aiming at determining more reasonable ACT strategies for stage III GC, the Japan Clinical Cancer Research Organization (JACCRO) randomly assigned 915 participants to an S-1 plus docetaxel group or S-1 group in the JACCRO GC-07 trial (18,19). The second interim analysis showed that the 3-year RFS of the S-1 plus docetaxel group (65.9%) was significantly superior to that of the S-1 group at 49.6% (HR, 0.632; 99% CI, 0.400–0.998; P=0.0007); furthermore, the addition of docetaxel inhibited multiple types of recurrence, including hematogenous, lymphatic and peritoneal recurrence, in stage III GC. The stage II GC subgroup has also been exclusively studied. The Japan Clinical Oncology Group (JCOG) conducted the JCOG1104 trial (20) focused on identifying the optimal duration of S-1 for stage II GC, and the primary endpoint also highlighted the “addition” trend. The 3-year RFS in the 8-course arm was 93.1%, and that of the 4-course arm was 89.8% (HR, 1.84; 95% CI, 0.93–3.63); while the 3-year OS in the 8-course arm (96.1%) was significantly superior to that of the 4-course arm at 92.6% (HR, 3.34; 95% CI, 1.22–9.12), indicating the effectiveness of this “addition” ACT duration for GC. Moreover, considering the efficacy, acceptable toxicity and
high compliance, the study concluded that S-1 ACT for stage II GC should continue for 12 months. After a serious amount of research based on staging workup explorations, we may provide better ACT strategies for local GC: S-1 for 1 year is necessary for stage II disease; S-1 plus docetaxel for 6 months and followed by S-1 alone for 6 months is a good choice for stage III disease. Furthermore, survival outcomes of the full analysis set of the SOXaGC trial and J-CLASSIC trial were assessed to evaluate which strategies have a better benefit for GC: S-1 plus oxaliplatin (SOX) or capcitabine plus oxaliplatin (CAPOX/XELOX) (21). The analysis suggested that although SOX and CAPOX have similar efficacy for stage III GC patients after D2 gastrectomy, adjuvant SOX appeared to be more favorable than CAPOX with regard to DFS among subgroups of patients younger than 65 years with stages IIIB and IIIC disease. The analysis put forward another clinical research direction about the differences in the treatment efficacy regarding sex and histologic type, which need further evaluation. Additionally, on the basis of the superiority of “addition” ACT, some trials to investigate whether further “addition” ACT may benefit selected GC subgroups are ongoing. For example, to validate the superiority of triplet over doublet regimens, the GASTFOX trial is comparing 5-fluorouracil and oxaliplatin (FOLFOX) without or with docetaxel (TFOX protocol) as first-line treatment for locally advanced or metastatic GC (22). Thus far, research on “addition” ACT trials for GC subgroups at specific stages has achieved great progress in making ACT more tailored and personalized with consideration of pathology stages. Additionally, for more selected high-risk GC patients (stage IIIb/IIIc), a longer duration or more intensive ACT might be worth of further exploration.

Inspired and enlightened by this development, we suggest that more specific stage subgroups, such as stage IIA/IIB/IIIA/IIIC or N1/N2/N3a/N3b, should be evaluated. Moreover, future trials may be designed based on histological and biological characteristics to assess the tailored ACT for specific subgroups [e.g., signet ring cell (SRC)].

**Designing ACT trials focused on node status**

Recently, a study conducted by Massachusetts General Hospital (MGH) showed that cancer cells from metastatic LNs can escape into the blood circulation and become the main source of cancer cells for distant metastasis in mouse models (23). At almost the same time, the same conclusion was independently obtained at the Medical University of Vienna using different methodologies (24). If human GC is comparable to the mouse model that LNs are active hubs for systemic tumor cell spread, GC patients with extensive LN metastasis are liable to the status that cancer cells have been widely released into the blood circulation from metastatic LNs. Consistently, LN metastasis has been demonstrated to be the strongest predictor of disease recurrence for GC (3, 25-27). Thus, high-LN-burden (e.g., N3a and N3b status) GC patients, regardless of T stage, might need more intense ACT (if patients have a good performance status and are able to tolerate more aggressive cytotoxic chemotherapeutics), even after radical gastrectomy and lymphadenectomy. Moreover, some researchers have found that the status of micrometastasis in regional LNs, which cannot be detected by conventional pathologic examination, may be associated with recurrence in node-negative status (pN0) patients (28-33). Some studies have reported that LN micrometastasis confers a poor prognosis (34,35). Hence, for locally advanced GC patients with a pN0 status, ACT may also decrease the risk of cancer cell release from potential micrometastatic LNs. Of note, the optimal extent of lymphadenectomy for local advanced GC remains controversial; D2 lymphadenectomy is routinely performed for locally advanced GC in East Asia, whereas surgeons in Western countries tend to perform D1 lymphadenectomy (5). Thus, we might need to distinguish these two types of patients in ACT programs when postoperative pathology confirms LN metastasis and picks relatively intense ACT regimens for Western patients who received D1 lymphadenectomy.

In addition, based on the above analysis, we sought to determine whether the “addition” trend of postoperative ACT might be extended to early GC with limited LN metastasis (e.g., pT1N1M0). At present, there is no consensus on whether postoperative ACT for diagnosed pT1N1M0 cases can improve patient’ prognosis. The retrospective analysis at Asia Centre suggested that patients with pT1N1 (1 or 2 LN involvement) GC might not benefit from postoperative ACT (21). However, we note that 95% of the patients in this trial underwent D2 lymphadenectomy, with different histology types; the extent of LN dissection might be attributed to marked disparities in outcomes between Eastern and Western patients, and histology characteristics might also affect the prognosis (5,36). The same situation has occurred in other
Asian studies (37,38). In contrast, analysis of pT1N1 patients in Western population using the National Cancer Database (NCDB), with most participants undergoing D1/D1+lymphadenectomy, resulted in the opposite conclusions (39). Among pT1N1 patients, ACT and adjuvant chemoradiation therapy (ACRT) significantly improved OS compared with surgery alone (HR, 0.37; 95% CI, 0.22–0.65 and HR, 0.40; 95% CI, 0.28–0.57). Therefore, this trial suggested that ACT, with or without concomitant radiation, might have a valuable role in Western pT1N1 GC patients. Considering the biological characteristics of metastatic LNs and the potential micrometastasis in regional LNs, pT1N1 GC patients not treated with D2 lymphadenectomy should be assessed for ACT. Further studies are necessary to reveal specific pT1N1 GC subgroups who might benefit from adjuvant treatments.

**Designing ACT research based on histological and biological characteristics**

As discussed above, research strategies of conducting “addition” ACT trials for specific stages of GC have achieved great progress in making ACT more tailored and personalized with consideration of pathology stages. Nonetheless, these ACT strategies can be even more tailored and personalized. Enlightened by previous and current research, we propose that future trials should be designed based on the histological and biological characteristics.

For example, SRC has specific biological potential features, including less differentiated and more infiltrative behavior and the potential of chemoresistance. Analyzing a cohort in Europe, Piessen et al. reported that SRC is a major and independent predictor of a dismal prognosis due to the aggressive behavior, such as a higher rate of peritoneal carcinomatosis and lymph node invasion (40). In contrast, analyses of a cohort of Western patients and patients in a high-volume center in Asia showed that when stratifying survival by tumor stage, the prognosis is paradoxically better for SRC tumors at early stages but worse as the disease progresses compared to non-SRC tumors (41,42). These findings suggest that driver mutations controlling the potential of SRC infiltration and metastasis may proceed as carcinogenesis develops. Additionally, studies have reported chemoresistance in SRC GC. In a cohort in Europe, the response to neoadjuvant chemotherapy was rare in SRC, though it was associated with improved outcomes (43). Another multicenter comparative study in Europe demonstrated that perioperative chemoradiation therapy with fluorouracil-platinum doublet or triplet regimens did not provide any survival advantage in SRC GC, which continued to progress during treatment (44). These results suggest that chemotherapeutic insensitivity is attributed to the absence of both cytotoxic and cytostatic effects. However, intriguingly, the FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) scheme as perioperative chemotherapy can achieve a good response in SRC tumors according to the preliminary data of the phase 2 part of the phase 2/3 FLOT4-AIO trial (45).

Therefore, tailored therapeutic strategies for SRC cancers, not only surgical approaches but also the chemotherapy regimens, should be highlighted. By reviewing the literature of SRC GC, Mengardo et al. proposed that multimodal treatment of SRC require special considerations with regard to the choice of the best therapeutic option (46). Thus, stratification based on SRC GC (or stratification according to the SRC subtype) to examine different therapeutic strategies and/or chemotherapy regimens and studies of chemoresistance biology to find specific signaling pathway targets for SRC should be included in subsequent clinical trials to identify more specific strategies. For example, considering the inherent chemotherapy resistance of SRC GC, the benefits of delaying surgery to pursue a neoadjuvant approach for SRC GC arouse doubts. Accordingly, a prospective multicenter controlled randomized phase II/III trial (PRODIGE-19-FFCD1103-ADCI002) was conducted to compare the strategy of perioperative chemotherapy (2×3 cycles of epirubicin, cisplatin, 5-fluorouracil) with a management of surgery followed by adjuvant chemotherapy (6 cycles of epirubicin, cisplatin, 5-fluorouracil) (47). The results of this trial may further help in devising individualized protocols of patient care in GC group in which diversity increasingly demands assessment of alternative strategies. More trials dedicated to this histological subtype to determine tailored treatment are awaited.

Similarly, some research has demonstrated that the diffuse histological type according to Lauren is the determinant for positive peritoneal cytology and peritoneal recurrence after surgery (48). It has been proven that S-1 chemotherapy might decrease the risk of peritoneal recurrence (6,21). By combining full analysis of the SOXaGC and J-CLASSIC trials, Nakamura found that
diffuse-type disease, female sex, age younger than 65 years, and stages IIIB and IIIC disease appeared to be favorable factors for adjuvant SOX (21). Thus, differences in treatment efficacy concerning sex and histologic type may be useful for selecting treatment among several options, though more solid evidence by further evaluation is needed. Similarly, the ARTIST 2 trial randomly allocated 538 local AGC patients with LN metastasis to receive S-1 alone for 12 months, S-1 plus oxaliplatin (SOX group) for 6 months or SOX plus radiotherapy with 45 Gy (SOXRT group) (49). The results were consistent with the trend of “addition” ACT in these subgroups, indicating that SOX/SOXRT is superior to S-1 alone for DFS among locally advanced GC patients with positive LNs.

Therefore, future trials designed based on histological and biological characteristics to determine tailored treatment for specific subgroups are urgently needed.

**Further extension of “addition” tendency in ACT for specific subgroups**

Further extension in the “addition” tendency in ACT for specific subgroups of GC patients might be local ACT [hyperthermic intraperitoneal chemotherapy (HIPEC)]. Breaking the “plasma-peritoneal barrier” and increasing the cytotoxic activity of chemotherapy by a synergistic effect with hyperthermia, prophylactic HIPEC (P-HIPEC) can eradicate free cancer cells and micrometastases in the peritoneal cavity, intraoperatively or soon after curative gastrectomy, to reduce peritoneal recurrences. Similar to the role of HIPEC in GC with peritoneal carcinomatosis (50), many clinical trials have also proven that P-HIPEC can reduce peritoneal recurrence and improve prognosis of locally advanced GC patients (51-56). Future trials should be designed to include more specific subgroups with a high risk of peritoneal recurrence. There are some ongoing trials to identify the efficacy of specific management for specific subgroups. For example, the phase III HIPEC-01 trial (ClinicalTrials.gov NCT02240524) investigated Paclitaxel (PTX)-based P-HIPEC for T3–T4b GC patients undergoing radical gastrectomy with D2 lymphadenectomy. In addition, the GAPS trial (UMIN000013109) evaluated intraperitoneal (IP) PTX plus S-1/PTX for curatively resectable GC with serosal invasion (57). We suggest that the addition of P-HIPEC in other subgroups with risk factors of peritoneal recurrences, such as Bormann type 4, venous invasion, diffuse-type classification or positive peritoneal washing cytology (CY+) (58-62), should be further verified in future trials.

**Implications and concerns**

“Addition” ACT research based on GC subgroups at specific pathology stages has achieved great progress in making ACT more tailored and personalized with the consideration of pathology stages. Thus, “addition” ACT strategies for subgroups of GC patients based on histological characteristics should be promoted. Considering the biological specificity of LN metastasis in GC, ACT trials focused on different node statuses should also be investigated. Indeed, future trials designed based on histological and biological characteristics to determine tailored treatment for specific subgroups are urgently needed and conducted as the theme of 2019 ASCO: Caring for Every Patient, Learning from Every Patient.

Of course, in the West, other multidisciplinary adjunctive approaches in addition to surgery, such as neoadjuvant chemotherapy (63), neoadjuvant chemoradiotherapy (64) and adjuvant chemoradiotherapy (65), have also confirmed a survival benefit compared with surgery alone. Perioperative chemotherapy has become the standard approach based on the positive results of the FLOT4 trial in the West (66). Hence, these investigations raise solid doubt about the role of ACT. However, there is also concern about the applicability of treatment models in the West to the East. Comparisons among all these treatment models have not been performed and are awaited.

**Acknowledgements**

This study was supported by the National Natural Science Foundation of China (No. 81872013); National Key Research and Development Program (No.2017YFC0108300); National Key Clinical Specialty Discipline Construction Program of China (No. [2012]121); Science and Technology Planning Project of Guangdong Province (No.2017B020226005).

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**

1. Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for
advanced gastric cancer: A Randomized controlled trial. J Clin Oncol 2016;34:1350-7.
2. Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: The CLASS-01 Randomized Clinical Trial. JAMA 2019;321:1983-92.
3. Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016;22:2875-93.
4. Ueno T, Iida M, Yoshino S, et al. East versus west: differences in surgical management in Asia compared with Europe and North America. Surg Clin North Am 2017;97:453-66.
5. Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med 2019;70:353-67.
6. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93.
7. Noh SH, Park SR, Yang HK, et al. Adjuvant capcitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96.
8. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-37.
9. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology 2008;9:215-21.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
11. Takahari D, Hamaguchi T, Yoshimura K, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011;67:1423-8.
12. Tamura S, Fujitani K, Kimura Y, et al. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy. Oncology 2011;80:296-300.
13. Hu X, Chen L, Du Y, et al. Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial. Chin J Cancer Res 2017;29:144-8.
14. Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer 2017;20:175-81.
15. Fujitani K, Tamura S, Kimura Y, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer 2014;17:348-53.
16. Yoon S, Yoo C, Ryu MH, et al. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIIB-IV gastric cancer. Gastric Cancer 2017;20:182-9.
17. Iacovelli R, Pietrantonio F, Maggi C, et al. Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. Crit Rev Oncol Hematol 2016;98:24-8.
18. Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim Analysis of JACCRO GC-07, a randomized controlled Trial. J Clin Oncol 2019;37:1296-1304.
19. Kodera Y, Yoshida K, Kochi M, et al. A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). J Clin Oncol 2018;36S:4007.
20. Yoshikawa T, Terashima M, Mizusawa J, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 2019;4:208-16.
21. Nakamura Y, Yamanaka T, Chin K, et al. Survival outcomes of two phase 2 studies of adjuvant chemotherapy with S-1 plus oxaliplatin or
capecitabine plus oxaliplatin for patients with gastric cancer after D2 gastrectomy. Ann Surg Oncol 2019;26:465-72.

22. Zaanan A, Samalin E, Aparicio T, et al. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). Dig Liver Dis 2018;50:408-10.

23. Pereira ER, Kedrin D, Seano G, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 2018;359:1403-7.

24. Brown M, Assen FP, Leithner A, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 2018;359:1408-11.

25. Wu CW, Hsieh MC, Lo SS, et al. Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci 1997;42:1265-9.

26. Marrelli D, Pedrazzani C, Corso G, et al. Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg 2009;250:43-50.

27. Zhou Y, Yu F, Wu L, et al. Survival after gastrectomy in node-negative gastric cancer: a review and meta-analysis of prognostic factors. Med Sci Monit 2015;21:1911-9.

28. Maehara Y, Oshiro T, Endo K, et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 1996;119:397-402.

29. Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg 1996;83:1144-7.

30. Ishida K, Katsuyama T, Sugiyama A, et al. Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. Cancer 1997;79:1069-76.

31. Deng J, Liang H, Sun D, et al. Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence. Can J Gastroenterol 2008;22:835-9.

32. Saito H, Kuroda H, Matsunaga T, et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol 2010;101:622-5.

33. Ru Y, Zhang L, Chen Q, et al. Detection and clinical significance of lymph node micrometastasis in gastric cardia adenocarcinoma. J Int Med Res 2012;40:293-9.

34. Harrison LE, Choe JK, Goldstein M, et al. Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients. J Surg Oncol 2000;73:153-7.

35. Yasuda K, Adachi Y, Shiraishi N, et al. Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol 2002;9:771-4.

36. Nelson R, Ko EB, Arrington A, et al. Race and correlations between lymph node number and survival for patients with gastric cancer. J Gastrointest Surg 2013;17:471-81.

37. Kim SM, An JY, Lee J, et al. Adjuvant chemotherapy versus chemoradiotherapy versus surgery alone for early gastric cancer with one or two lymph node metastasis. Ann Surg Oncol 2018;25:1616-24.

38. Shin HB, An JY, Lee SH, et al. Is adjuvant chemotherapy necessary in pT1N1 gastric cancer? BMC Cancer 2017;17:287.

39. Hester CA, Augustine MM, Mansour JC, et al. Adjuvant therapy is associated with improved survival in pT1N1 gastric cancer in a heterogeneous Western patient population. Ann Surg Oncol 2019;26:167-76.

40. Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009;250:878-87.

41. Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol 2014;21:1678-85.

42. Chon HJ, Hyung WJ, Kim C, et al. Differential prognostic implications of gastric signet ring cell carcinoma stage adjusted analysis from a single high-volume center in Asia. Ann Surg 2017;265:946-53.

43. Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol 2014;21:1739-48.

44. Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival
in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011;254:684-93.

45. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697-708.

46. Mengardo V, Treppiedi E, Bencivenga M, et al. Tailored treatment for signet ring cell gastric cancer. Updates Surg 2018;70:167-71.

47. Piessen G, Messager M, Le Malicot K, et al. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19- FFCD1103- ADCI002. BMC Cancer 2013;13:281.

48. Lisiecki R, Spychala A, Pater K, et al. Analysis of risk factors of positive peritoneal cytology in patients treated for gastric cancer — preliminary report. Pol Przegl Chir 2015;87:506-12.

49. Park SH, Zang DY, Han B, et al. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol 2019;37S:403.

50. Ellison LM, Man Y, Stojadinovic A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. Chin J Cancer Res 2017;29:86-92.

51. Hamazoe R, Maeta M, Kaibara N. Intrapерitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048-52.

52. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529-34.

53. Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 1999;57:106-14.

54. Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347-54.

55. Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol 2010;101:457-64.

56. Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 2012;12:526.

57. Ito S, Imano M, Uenosono Y, et al. A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study. J Clin Oncol 2018;36S:403.

58. Lee JH, Son SY, Lee CM, et al. Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer 2014;17:529-36.

59. Zhao J, Zhou R, Zhang Q, et al. Establishment of risk evaluation model of peritoneal metastasis in gastric cancer and its predictive value. Zhonghua Wei Chang Wai Ke Za Zhi (in Chinese) 2017;20:47-52.

60. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347-53.

61. Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-56.

62. Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 2017.

63. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.

64. Shapiro J, van Lanschot JJB, Hulshof Mccm, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-98.

65. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.

66. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluourouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57.

Cite this article as: Chen X, Liu H, Li G, Yu J. Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next? Chin J Cancer Res 2019;31(6):892-900. doi: 10.21147/j.issn.1000-9604.2019.06.05